

abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

Please cancel claims 38-39 and 43 without prejudice or disclaimer.

Please substitute the following claim 37 for the pending claim 37:

F¹ 37. (Amended twice) A pharmaceutical composition suitable for aerosol delivery comprising a nucleic acid encoding a nitric oxide synthase gene operably linked to a pulmonary tissue specific expression control element, an adenoviral vector and a pharmaceutically acceptable carrier vehicle.

Please substitute the following claim 40 for the pending claim 40:

F² 40. (Amended once) A method of inducing pulmonary vasodilation comprising: administering, by aerosol administration, to a mammal in need of pulmonary vasodilation an effective amount of the pharmaceutical composition of claim 37; and an effective amount of at least one drug selected from the group consisting of an immunosuppressive agent and a phosphodiesterase inhibitor; wherein inducing said pulmonary vasodilation does not significantly affect systemic blood pressure or cardiac index.